earnings
confidence high
sentiment neutral
materiality 0.75
Biogen Q1 revenue up 6% to $2.43B; Non-GAAP EPS $3.02 impacted by $165M Stoke upfront
BIOGEN INC.
2025-Q1 EPS reported
$1.64
revenue$2,431,000,000
- GAAP diluted EPS $1.64, Non-GAAP $3.02; both down YoY due to ~($0.95) impact from Stoke upfront payment.
- LEQEMBI global in-market sales ~$96M; SKYCLARYS global revenue ~$124M; launch products more than doubled YoY.
- Updated FY2025 non-GAAP EPS guidance $14.50-$15.50; total revenue expected to decline mid-single-digit constant currency.
- Felzartamab Phase 3 study initiated in antibody-mediated rejection; BIIB080 (tau ASO) received FDA Fast Track designation.
- Zorevunersen collaboration with Stoke ($165M upfront) for Dravet syndrome; pivotal Phase 3 to start in coming months.